MAZE.US Maze Therapeutics, Inc. Common Stock

Healthcare Pharmaceuticals USA Stocks
34.33 USD
Close of Nov 15, 2026
21.95 53.65
Market cap
USD 1.88B
P/E
-
P/B
4.38x
ROE
-36.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MAZE.US undervalued?

Graham number

The Graham number of Maze Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Maze Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Maze Therapeutics, Inc. Common Stock yet.

Maze Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Maze Therapeutics, Inc. Common Stock

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatme…

Full company profile